헬리코박터 파일로리의 3차 구제요법에서 리파부틴과 레보플록사신의 비교

• Published in: The Korean journal of gastroenterology Vol. 59; no. 6; pp. 401 - 406
• Main Authors: 정명호, Myung Ho Jeong, 정준원, Jun Won Chung, 이상진, Sang Jin Lee, 하민수, Minsu Ha, 정석후, Seok Hoo Jeong, 나선영, Sunyoung Na, 나병수, Byung Soo Na, 박성근, Sung Keun Park, 김윤재, Yoon Jae Kim, 권광안, Kwang An Kwon, 고광일, Kwang Il Ko
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 30-06-2012
• Subjects: Helicobacter pylori; Levofloxacin; Rifabutin; Salvage therapy; Third Line; 내과학
• ISSN: 1598-9992; 2233-6869

Background/Aims: There is increasing need for third-line therapy of Helicobacter pylori due to increasing level of antibiotics resistance. The aim of this study was to compare rifabutin and levofloxacin rescue regimens in patients with first- and second-line Helicobacter pylori eradication failures. Methods: Patients, in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin and a second trial with proton pump inhibitor-bismuth-tetracycline-metronidazole had failed, received treatment with either rifabutin or levofloxacin, plus amoxicillin (1 g twice daily) and standard dose proton pump inhibitor. Eradication rates were confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy. Results: Eradication rates were 71.4% in the rifabutin group, and 57.1% in the levofloxacin group, respectively. Although there was no significant difference in Helicobacter pylori eradication rates between two groups (p=0.656), rifabutin based regimen showed relatively higher eradication rate. Conclusions: Helicobacter pylori eradication rates of rifabutin- or levofloxacin-based triple therapy could not achieve enough eradication rate. Further studies would be needed on combination of levofloxacin and rifabutin-based regimen or culture based treatment. (Korean J Gastroenterol 2012;59:401-406)